MedTrace Logo

An Evaluation of the Safety and Performance of the CathVision ECGenius® System.

NCT05301803 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2024-09-05

Study results available
· View outcomes & findings →

Summary

The primary objective is to evaluate the safety and technical performance of the CathVision ECGenius® System. The secondary objective is to benchmark the intracardiac electrogram signal quality compared to commercially available systems in patients undergoing assessment and ablation of cardiac arrhythmias.

Conditions

  • Cardiac Arrhythmia

Interventions

DEVICE

Electrophysiology procedure

Electrophysiology testing and cardiac ablation of arrhythmia

Sponsors & Collaborators

  • Medicept Inc.

    collaborator INDUSTRY

  • CathVision ApS

    lead INDUSTRY

Principal Investigators

  • Nathaniel C Thompson, MD PhD · The University of Vermont Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2022-04-30
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05301803 on ClinicalTrials.gov